Search research articles
Contact Us
Filters
Showing results (21-30 of 43) with videos related to
Page
of 5
Sort By:
British Journal of Cancer
|
February 16, 2023
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
Jayesh Desai, Peter Fong, Victor Moreno, et al.
Clinical Lung Cancer
|
August 12, 2020
Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC
Evangeline Samuel, Gabrielle Lie, Adithya Balasubramanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2020
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Oliver Klein, Damien Kee, Ben Markman, et al.
Targeted Oncology
|
December 1, 2017
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
Mark J McKeage, Dusan Kotasek, Ben Markman, et al.
Cancers
|
September 9, 2022
Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities
Belinda Lee, Lucy Gately, Sheau Wen Lok, et al.
Investigational New Drugs
|
July 8, 2018
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
Michael Carducci, Montaser Shaheen, Ben Markman, et al.
Journal for Immunotherapy of Cancer
|
November 16, 2021
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial
Oliver Klein, Damien Kee, Bo Gao, et al.
Cancer Research
|
October 3, 2008
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra, Ben Markman, Maurizio Scaltriti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
Luis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
Nature Medicine
|
March 1, 2024
A gut microbial signature for combination immune checkpoint blockade across cancer types
Ashray Gunjur, Yan Shao, Timothy Rozday, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 43) with videos related to
Sort By:
Page
of 5
British Journal of Cancer
|
February 16, 2023
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
Jayesh Desai, Peter Fong, Victor Moreno, et al.
Clinical Lung Cancer
|
August 12, 2020
Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC
Evangeline Samuel, Gabrielle Lie, Adithya Balasubramanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2020
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Oliver Klein, Damien Kee, Ben Markman, et al.
Targeted Oncology
|
December 1, 2017
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
Mark J McKeage, Dusan Kotasek, Ben Markman, et al.
Cancers
|
September 9, 2022
Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities
Belinda Lee, Lucy Gately, Sheau Wen Lok, et al.
Investigational New Drugs
|
July 8, 2018
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
Michael Carducci, Montaser Shaheen, Ben Markman, et al.
Journal for Immunotherapy of Cancer
|
November 16, 2021
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial
Oliver Klein, Damien Kee, Bo Gao, et al.
Cancer Research
|
October 3, 2008
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra, Ben Markman, Maurizio Scaltriti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
Luis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
Nature Medicine
|
March 1, 2024
A gut microbial signature for combination immune checkpoint blockade across cancer types
Ashray Gunjur, Yan Shao, Timothy Rozday, et al.
Page
of 5